Scarica l'app Stockscreener
1.21
6.14%
0.07
Pre-mercato:
1.19
-0.02
-1.65%
Inflarx N V Borsa (IFRX) Ultime notizie
InflaRx NV stock (NL0012661870): Why does its anti-inflammatory pipeline matter more now for biotech - AD HOC NEWS
IFRX Stock Price, Quote & Chart | INFLARX NV (NASDAQ:IFRX) - ChartMill
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition - TipRanks
InflaRx (Nasdaq: IFRX) reports izicopan data showing no CYP3A4 time‑dependent inhibition - Stock Titan
New lab data point to lower liver toxicity risk for InflaRx pill - Stock Titan
InflaRx NV stock: Why this biotech innovator merits your watchlist now - AD HOC NEWS
InflaRx receives Nasdaq notification - MSN
Investment Review: Is InflaRx NV a top pick in the sector2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
IFRX Technical Analysis & Stock Price Forecast - Intellectia AI
InflaRx NV stock: Biotech innovator or high-risk bet? - AD HOC NEWS
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP - TipRanks
InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan
InflaRx N : Dutch Board Report including KPMG Auditor Report 2025 (InflaRx N.V. Dutch Board Report + Auditor Report 2025) - marketscreener.com
InflaRx N : Long-term Incentive Plan “LTIP 2026” (LTIP 2026 FINAL) - marketscreener.com
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - bitget.com
IFRX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
InflaRx presents phase 3 vilobelimab data at dermatology meeting By Investing.com - Investing.com South Africa
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - Bitget
InflaRx presents phase 3 vilobelimab data at dermatology meeting - Investing.com
InflaRx Highlights Clinical Activity of Vilobelimab in - GlobeNewswire
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Sell Signal: Can InflaRx NV deliver consistent dividends2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
If You Invested $1,000 in Inflarx (IFRX) - Stock Titan
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
Raymond James raises Inflarx stock price target on drug trial data By Investing.com - Investing.com South Africa
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com South Africa
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
After focusing on izicopan, InflaRx says cash lasts until mid-2027 - Stock Titan
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):